BioDelivery Sciences International Inc - ESG Rating & Company Profile powered by AI
This ESG score includes 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Life on Land'. This page includes a Q&A table for BioDelivery Sciences International Inc. This webpage of BioDelivery Sciences International Inc was prepared by All Street Sevva using advanced AI.
BioDelivery Sciences International Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | BioDelivery Sciences International Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does BioDelivery Sciences International Inc have an accelerator or VC vehicle to help deliver innovation?
Does BioDelivery Sciences International Inc disclose current and historical energy intensity?
Does BioDelivery Sciences International Inc report the average age of the workforce?
Does BioDelivery Sciences International Inc reference operational or capital allocation in relation to climate change?
Does BioDelivery Sciences International Inc disclose its ethnicity pay gap?
Does BioDelivery Sciences International Inc disclose cybersecurity risks?
Does BioDelivery Sciences International Inc offer flexible work?
Does BioDelivery Sciences International Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does BioDelivery Sciences International Inc disclose the number of employees in R&D functions?
Does BioDelivery Sciences International Inc conduct supply chain audits?
Does BioDelivery Sciences International Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does BioDelivery Sciences International Inc conduct 360 degree staff reviews?
Does BioDelivery Sciences International Inc disclose the individual responsible for D&I?
Does BioDelivery Sciences International Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does BioDelivery Sciences International Inc disclose current and / or historical scope 2 emissions?
Does BioDelivery Sciences International Inc disclose water use targets?
Does BioDelivery Sciences International Inc have careers partnerships with academic institutions?
Did BioDelivery Sciences International Inc have a product recall in the last two years?
Does BioDelivery Sciences International Inc disclose incidents of discrimination?
Does BioDelivery Sciences International Inc allow for Work Councils/Collective Agreements to be formed?
Has BioDelivery Sciences International Inc issued a profit warning in the past 24 months?
Does BioDelivery Sciences International Inc disclose parental leave metrics?
Does BioDelivery Sciences International Inc disclose climate scenario or pathway analysis?
Does BioDelivery Sciences International Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does BioDelivery Sciences International Inc disclose the pay ratio of women to men?
Does BioDelivery Sciences International Inc support suppliers with sustainability related research and development?
Does BioDelivery Sciences International Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does BioDelivery Sciences International Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is BioDelivery Sciences International Inc involved in embryonic stem cell research?
Does BioDelivery Sciences International Inc disclose GHG and Air Emissions intensity?
Does BioDelivery Sciences International Inc disclose its waste policy?
Does BioDelivery Sciences International Inc report according to TCFD requirements?
Does BioDelivery Sciences International Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does BioDelivery Sciences International Inc disclose energy use targets?
Does BioDelivery Sciences International Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does BioDelivery Sciences International Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for BioDelivery Sciences International Inc
These potential risks are based on the size, segment and geographies of the company.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.